FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis.

Fibroblast growth factor 21(FGF21) is an endocrine cytokine that targets inflammation and atherosclerosis (AS). However, the underlying molecular mechanisms of the FGF21 anti-AS effect remain to be explored. Pyroptosis induced by hyperlipidemia or oxidized low-density lipoprotein (oxLDL) in vascular endothelial cells (VECs) is a significant step in the advancement of AS. This work aimed to evaluate the mechanisms and functioning of FGF21 against AS using an atherosclerotic animal model and oxLDL mimic in vitro. We found that exogenous treatments with FGF21 significantly reduced the aortic sinus plaque area and ameliorated dyslipidemia in apoE-/- mice. FGF21 attenuated the expression of pyroptosis-related proteins both in vivo and in vitro. Possibly, FGF21 improves mitochondrial function, inhibits mitochondrial division, and reduces ROS production by maintaining mitochondrial dynamics and function to reduce NLRP3 related pyroptosis and inhibits VECs endoplasmic reticulum stress, thereby exerting an anti-atherosclerotic effect.